These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 29713453)

  • 1. Anti-CTLA-4 antibodies in cancer immunotherapy: selective depletion of intratumoral regulatory T cells or checkpoint blockade?
    Tang F; Du X; Liu M; Zheng P; Liu Y
    Cell Biosci; 2018; 8():30. PubMed ID: 29713453
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy.
    Du X; Tang F; Liu M; Su J; Zhang Y; Wu W; Devenport M; Lazarski CA; Zhang P; Wang X; Ye P; Wang C; Hwang E; Zhu T; Xu T; Zheng P; Liu Y
    Cell Res; 2018 Apr; 28(4):416-432. PubMed ID: 29472691
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3
    Sharma A; Subudhi SK; Blando J; Scutti J; Vence L; Wargo J; Allison JP; Ribas A; Sharma P
    Clin Cancer Res; 2019 Feb; 25(4):1233-1238. PubMed ID: 30054281
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Both intratumoral regulatory T cell depletion and CTLA-4 antagonism are required for maximum efficacy of anti-CTLA-4 antibodies.
    Lax BM; Palmeri JR; Lutz EA; Sheen A; Stinson JA; Duhamel L; Santollani L; Kennedy A; Rothschilds AM; Spranger S; Sansom DM; Wittrup KD
    Proc Natl Acad Sci U S A; 2023 Aug; 120(31):e2300895120. PubMed ID: 37487077
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of CTLA-4 checkpoint antibodies on ligand binding and Transendocytosis.
    Williams C; Kennedy A; Robinson MA; Lloyd C; Dovedi SJ; Sansom DM
    Front Immunol; 2022; 13():871802. PubMed ID: 36119113
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An anti-CTLA-4 heavy chain-only antibody with enhanced T
    Gan X; Shan Q; Li H; Janssens R; Shen Y; He Y; Chen F; van Haperen R; Drabek D; Li J; Zhang Y; Zhao J; Qin B; Jheng MJ; Chen V; Wang J; Rong Y; Grosveld F
    Proc Natl Acad Sci U S A; 2022 Aug; 119(32):e2200879119. PubMed ID: 35925889
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-CTLA-4 Activates Intratumoral NK Cells and Combined with IL15/IL15Rα Complexes Enhances Tumor Control.
    Sanseviero E; O'Brien EM; Karras JR; Shabaneh TB; Aksoy BA; Xu W; Zheng C; Yin X; Xu X; Karakousis GC; Amaravadi RK; Nam B; Turk MJ; Hammerbacher J; Rubinstein MP; Schuchter LM; Mitchell TC; Liu Q; Stone EL
    Cancer Immunol Res; 2019 Aug; 7(8):1371-1380. PubMed ID: 31239316
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fc-independent functions of anti-CTLA-4 antibodies contribute to anti-tumor efficacy.
    Sato Y; Casson CN; Matsuda A; Kim JI; Shi JQ; Iwasaki S; Chen S; Modrell B; Chan C; Tavares D; Austen D; Ida K; Tayber O; Hein P; Comeau R; Lin Y; Shaw MH
    Cancer Immunol Immunother; 2022 Oct; 71(10):2421-2431. PubMed ID: 35237846
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanism- and Immune Landscape-Based Ranking of Therapeutic Responsiveness of 22 Major Human Cancers to Next Generation Anti-CTLA-4 Antibodies.
    Zhang P; Xiong X; Rolfo C; Du X; Zhang Y; Yang H; Russo A; Devenport M; Zhou P; Liu Y; Zheng P
    Cancers (Basel); 2020 Jan; 12(2):. PubMed ID: 31991588
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A mutant B7-1/Ig fusion protein that selectively binds to CTLA-4 ameliorates anti-tumor DNA vaccination and counters regulatory T cell activity.
    Chakrabarti R; Zhou ZF; Chang Y; Prud'homme GJ
    Vaccine; 2005 Aug; 23(37):4553-64. PubMed ID: 15919138
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FcγRIIB Is an Immune Checkpoint Limiting the Activity of Treg-Targeting Antibodies in the Tumor Microenvironment.
    Knorr DA; Blanchard L; Leidner RS; Jensen SM; Meng R; Jones A; Ballesteros-Merino C; Bell RB; Baez M; Marino A; Sprott D; Bifulco CB; Piening B; Dahan R; Osorio JC; Fox BA; Ravetch JV
    Cancer Immunol Res; 2024 Mar; 12(3):322-333. PubMed ID: 38147316
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Addressing the Elephant in the Immunotherapy Room: Effector T-Cell Priming versus Depletion of Regulatory T-Cells by Anti-CTLA-4 Therapy.
    Hong MMY; Maleki Vareki S
    Cancers (Basel); 2022 Mar; 14(6):. PubMed ID: 35326731
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Opposing roles of CD28:B7 and CTLA-4:B7 pathways in regulating in vivo alloresponses in murine recipients of MHC disparate T cells.
    Blazar BR; Taylor PA; Panoskaltsis-Mortari A; Sharpe AH; Vallera DA
    J Immunol; 1999 Jun; 162(11):6368-77. PubMed ID: 10352249
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Remarkably similar CTLA-4 binding properties of therapeutic ipilimumab and tremelimumab antibodies.
    He M; Chai Y; Qi J; Zhang CWH; Tong Z; Shi Y; Yan J; Tan S; Gao GF
    Oncotarget; 2017 Sep; 8(40):67129-67139. PubMed ID: 28978021
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A mathematical modelling tool for unravelling the antibody-mediated effects on CTLA-4 interactions.
    Ganesan A; Arulraj T; Choulli T; Barakat KH
    BMC Med Inform Decis Mak; 2018 Jun; 18(1):37. PubMed ID: 29890992
    [TBL] [Abstract][Full Text] [Related]  

  • 16. B7+ iris pigment epithelial cells convert T cells into CTLA-4+, B7-expressing CD8+ regulatory T cells.
    Sugita S; Keino H; Futagami Y; Takase H; Mochizuki M; Stein-Streilein J; Streilein JW
    Invest Ophthalmol Vis Sci; 2006 Dec; 47(12):5376-84. PubMed ID: 17122127
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells.
    Selby MJ; Engelhardt JJ; Quigley M; Henning KA; Chen T; Srinivasan M; Korman AJ
    Cancer Immunol Res; 2013 Jul; 1(1):32-42. PubMed ID: 24777248
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FcyRIIB is a novel immune checkpoint in the tumor microenvironment limiting activity of Treg-targeting antibodies.
    Knorr D; Leidner R; Jensen S; Meng R; Jones A; Ballesteros-Merino C; Bell RB; Baez M; Sprott D; Bifulco C; Piening B; Dahan R; Fox BA; Ravetch J
    bioRxiv; 2023 Jan; ():. PubMed ID: 36711504
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structural basis for cancer immunotherapy by the first-in-class checkpoint inhibitor ipilimumab.
    Ramagopal UA; Liu W; Garrett-Thomson SC; Bonanno JB; Yan Q; Srinivasan M; Wong SC; Bell A; Mankikar S; Rangan VS; Deshpande S; Korman AJ; Almo SC
    Proc Natl Acad Sci U S A; 2017 May; 114(21):E4223-E4232. PubMed ID: 28484017
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25.
    Hannani D; Vétizou M; Enot D; Rusakiewicz S; Chaput N; Klatzmann D; Desbois M; Jacquelot N; Vimond N; Chouaib S; Mateus C; Allison JP; Ribas A; Wolchok JD; Yuan J; Wong P; Postow M; Mackiewicz A; Mackiewicz J; Schadendorff D; Jaeger D; Zörnig I; Hassel J; Korman AJ; Bahjat K; Maio M; Calabro L; Teng MW; Smyth MJ; Eggermont A; Robert C; Kroemer G; Zitvogel L
    Cell Res; 2015 Feb; 25(2):208-24. PubMed ID: 25582080
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.